Structure-Activity Relationship Studies of the Two-Component Lantibiotic Haloduracin

Chemistry and Biology

Volumn 15, Issue 10, 2008, Pages 1035-1045

  Cooper, Lisa E ^a   McClerren, Amanda L ^a   Chary, Anita ^a   van der Donk, Wilfred A ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

CHEMBIO

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIOCIN; HALODURACIN, BACILLUS HALODURANS; PEPTIDE HYDROLASE; SULFIDE;

ARTICLE; BACILLUS; BIOSYNTHESIS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; ENZYME SPECIFICITY; MASS SPECTROMETRY; METABOLISM; MICROBIAL VIABILITY; MOLECULAR GENETICS; STRUCTURE ACTIVITY RELATION;

ANTI-BACTERIAL AGENTS; BACILLUS; BACTERIOCINS; MICROBIAL VIABILITY; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; PEPTIDE HYDROLASES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; SULFIDES;

EID: 53649090841     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2008.07.020     Document Type: Article

References (49)

1. Bierbaum G., Szekat C., Josten M., Heidrich C., Kempter C., Jung G., and Sahl H.G. Engineering of a novel thioether bridge and role of modified residues in the lantibiotic Pep5. Appl. Environ. Microbiol. 62 (1996) 385-392
2. Brötz H., Bierbaum G., Leopold K., Reynolds P.E., and Sahl H.G. The lantibiotic mersacidin inhibits peptidoglycan synthesis by targeting lipid II. Antimicrob. Agents Chemother. 42 (1998) 154-160
3. Castiglione F., Lazzarini A., Carrano L., Corti E., Ciciliato I., Gastaldo L., Candiani P., Losi D., Marinelli F., Selva E., et al. Determining the structure and mode of action of microbisporicin, a potent lantibiotic active against multiresistant pathogens. Chem. Biol. 15 (2008) 22-31
4. Chatterjee S., Chatterjee S., Lad S.J., Phansalkar M.S., Rupp R.H., Ganguli B.N., Fehlhaber H.W., and Kogler H. Mersacidin, a new antibiotic from Bacillus. Fermentation, isolation, purification and chemical characterization. J. Antibiot. (Tokyo) 45 (1992) 832-838
5. Chatterjee C., Miller L.M., Leung Y.L., Xie L., Yi M., Kelleher N.L., and van der Donk W.A. Lacticin 481 synthetase phosphorylates its substrate during lantibiotic production. J. Am. Chem. Soc. 127 (2005) 15332-15333
6. Chatterjee C., Paul M., Xie L., and van der Donk W.A. Biosynthesis and mode of action of lantibiotics. Chem. Rev. 105 (2005) 633-684
7. Chatterjee C., Patton G.C., Cooper L., Paul M., and van der Donk W.A. Engineering dehydro amino acids and thioethers into peptides using lacticin 481 synthetase. Chem. Biol. 13 (2006) 1109-1117
8. Chen P., Novak J., Kirk M., Barnes S., Qi F., and Caufield P.W. Structure-activity study of the lantibiotic mutacin II from Streptococcus mutans T8 by a gene replacement strategy. Appl. Environ. Microbiol. 64 (1998) 2335-2340
9. Chen P., Qi F.X., Novak J., Krull R.E., and Caufield P.W. Effect of amino acid substitutions in conserved residues in the leader peptide on biosynthesis of the lantibiotic mutacin II. FEMS Microbiol. Lett. 195 (2001) 139-144
10. Corvey C., Stein T., Dusterhus S., Karas M., and Entian K.D. Activation of subtilin precursors by Bacillus subtilis extracellular serine proteases subtilisin (AprE), WprA, and Vpr. Biochem. Biophys. Res. Commun. 304 (2003) 48-54
11. Cotter P.D., Hill C., and Ross R.P. Bacterial lantibiotics: strategies to improve therapeutic potential. Curr. Protein Pept. Sci. 6 (2005) 61-75
12. Cotter P.D., Deegan L.H., Lawton E.M., Draper L.A., O'Connor P.M., Hill C., and Ross R.P. Complete alanine scanning of the two-component lantibiotic lacticin 3147: generating a blueprint for rational drug design. Mol. Microbiol. 62 (2006) 735-747
13. Cox C.R., Coburn P.S., and Gilmore M.S. Enterococcal cytolysin: a novel two component peptide system that serves as a bacterial defense against eukaryotic and prokaryotic cells. Curr. Protein Pept. Sci. 6 (2005) 77-84
14. Delves-Broughton J., Blackburn P., Evans R.J., and Hugenholtz J. Applications of the bacteriocin, nisin. Antonie Van Leeuwenhoek 69 (1996) 193-202
15. Field D., Collins B., Cotter P.D., Hill C., and Ross R.P. A system for the random mutagenesis of the two-peptide lantibiotic lacticin 3147: analysis of mutants producing reduced antibacterial activities. J. Mol. Microbiol. Biotechnol. 13 (2007) 226-234
16. Furgerson Ihnken L.A., Chatterjee C., and van der Donk W.A. In vitro reconstitution and substrate specificity of a lantibiotic protease. Biochemistry 47 (2008) 7352-7363
17. Galvin M., Hill C., and Ross R.P. Lacticin 3147 displays activity in buffer against gram-positive bacterial pathogens which appear insensitive in standard plate assays. Lett. Appl. Microbiol. 28 (1999) 355-358
18. Garneau S., Martin N.I., and Vederas J.C. Two-peptide bacteriocins produced by lactic acid bacteria. Biochimie 84 (2002) 577-592
19. Håvarstein L.S., Diep D.B., and Nes I.F. A family of bacteriocin ABC transporters carry out proteolytic processing of their substrates concomitant with export. Mol. Microbiol. 16 (1995) 229-240
20. Holo H., Jeknic Z., Daeschel M., Stevanovic S., and Nes I.F. Plantaricin W from Lactobacillus plantarum belongs to a new family of two-peptide lantibiotics. Microbiology 147 (2001) 643-651
21. Hsu S.T., Breukink E., Bierbaum G., Sahl H.G., de Kruijff B., Kaptein R., van Nuland N.A., and Bonvin A.M. NMR study of mersacidin and lipid II interaction in dodecylphosphocholine micelles. Conformational changes are a key to antimicrobial activity. J. Biol. Chem. 278 (2003) 13110-13117
22. Hyink O., Balakrishnan M., and Tagg J.R. Streptococcus rattus strain BHT produces both a class I two-component lantibiotic and a class II bacteriocin. FEMS Microbiol. Lett. 252 (2005) 235-241
23. Kruszewska D., Sahl H.G., Bierbaum G., Pag U., Hynes S.O., and Ljungh A. Mersacidin eradicates methicillin-resistant Staphylococcus aureus (MRSA) in a mouse rhinitis model. J. Antimicrob. Chemother. 54 (2004) 648-653
24. Kuipers O.P., Bierbaum G., Ottenwälder B., Dodd H.M., Horn N., Metzger J., Kupke T., Gnau V., Bongers R., van den Bogaard P., et al. Protein engineering of lantibiotics. Antonie Van Leeuwenhoek 69 (1996) 161-169
25. Lawton E.M., Cotter P.D., Hill C., and Ross R.P. Identification of a novel two-peptide lantibiotic, Haloduracin, produced by the alkaliphile Bacillus halodurans C-125. FEMS Microbiol. Lett. 267 (2007) 64-71
26. Levengood M.R., Patton G.C., and van der Donk W.A. The leader peptide is not required for post-translational modification by lacticin 481 synthetase. J. Am. Chem. Soc. 129 (2007) 10314-10315
27. Li B., and van der Donk W.A. Identification of essential catalytic residues of the cyclase NisC involved in the biosynthesis of nisin. J. Biol. Chem. 282 (2007) 21169-21175
28. Li B., Yu J.-P.J., Brunzelle J.S., Moll G.N., van der Donk W.A., and Nair S.K. Structure and mechanism of the lantibiotic cyclase involved in nisin biosynthesis. Science 311 (2006) 1464-1467
29. Lubelski J., Rink R., Khusainov R., Moll G.N., and Kuipers O.P. Biosynthesis, immunity, regulation, mode of action and engineering of the model lantibiotic nisin. Cell. Mol. Life Sci. 65 (2008) 455-476
30. Martin N.I., Sprules T., Carpenter M.R., Cotter P.D., Hill C., Ross R.P., and Vederas J.C. Structural characterization of lacticin 3147, a two-peptide lantibiotic with synergistic activity. Biochemistry 43 (2004) 3049-3056
31. McClerren A.L., Cooper L.E., Quan C., Thomas P.M., Kelleher N.L., and van der Donk W.A. Discovery and in vitro biosynthesis of haloduracin, a new two-component lantibiotic. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 17243-17248
32. Morgan S.M., O'Connor P.M., Cotter P.D., Ross R.P., and Hill C. Sequential actions of the two component peptides of the lantibiotic lacticin 3147 explain its antimicrobial activity at nanomolar concentrations. Antimicrob. Agents Chemother. 49 (2005) 2606-2611
33. Nes I.F., and Tagg J.R. Novel lantibiotics and their pre-peptides. Antonie Van Leeuwenhoek 69 (1996) 89-97
34. Ottenwälder B., Kupke T., Brecht S., Gnau V., Metzger J., Jung G., and Götz F. Isolation and characterization of genetically engineered gallidermin and epidermin analogs. Appl. Environ. Microbiol. 61 (1995) 3894-3903
35. Patton G.C., Paul M., Cooper L.E., Chatterjee C., and van der Donk W.A. The importance of the leader sequence for directing lanthionine formation in lacticin 481. Biochemistry 47 (2008) 7342-7351
36. Paul M., Patton G.C., and van der Donk W.A. Mutants of the zinc ligands of lacticin 481 synthetase retain dehydration activity but have impaired cyclization activity. Biochemistry 46 (2007) 6268-6276
37. Petersen F.C., Fimland G., and Scheie A.A. Purification and functional studies of a potent modified quorum-sensing peptide and a two-peptide bacteriocin in Streptococcus mutans. Mol. Microbiol. 61 (2006) 1322-1334
38. Pitts K.E., and Summers A.O. The roles of thiols in the bacterial organomercurial lyase (MerB). Biochemistry 41 (2002) 10287-10296
39. Rink R., Kuipers A., de Boef E., Leenhouts K.J., Driessen A.J., Moll G.N., and Kuipers O.P. Lantibiotic structures as guidelines for the design of peptides that can be modified by lantibiotic enzymes. Biochemistry 44 (2005) 8873-8882
40. Ryan M.P., Jack R.W., Josten M., Sahl H.G., Jung G., Ross R.P., and Hill C. Extensive post-translational modification, including serine to D-alanine conversion, in the two-component lantibiotic, lacticin 3147. J. Biol. Chem. 274 (1999) 37544-37550
41. Szekat C., Jack R.W., Skutlarek D., Farber H., and Bierbaum G. Construction of an expression system for site-directed mutagenesis of the lantibiotic mersacidin. Appl. Environ. Microbiol. 69 (2003) 3777-3783
42. van der Meer J.R., Rollema H.S., Siezen R.J., Beerthuyzen M.M., Kuipers O.P., and de Vos W.M. Influence of amino acid substitutions in the nisin leader peptide on biosynthesis and secretion of nisin by Lactococcus lactis. J. Biol. Chem. 269 (1994) 3555-3562
43. van Kraaij C., Breukink E., Rollema H.S., Bongers R.S., Kosters H.A., de Kruijff B., and Kuipers O.P. Engineering a disulfide bond and free thiols in the lantibiotic nisin Z. Eur. J. Biochem. 267 (2000) 901-909
44. Wiedemann I., Bottiger T., Bonelli R.R., Wiese A., Hagge S.O., Gutsmann T., Seydel U., Deegan L., Hill C., Ross P., et al. The mode of action of the lantibiotic lacticin 3147-a complex mechanism involving specific interaction of two peptides and the cell wall precursor lipid II. Mol. Microbiol. 61 (2006) 285-296
45. Willey J.M., and van der Donk W.A. Lantibiotics: peptides of diverse structure and function. Annu. Rev. Microbiol. 61 (2007) 477-501
46. Xie L., Miller L.M., Chatterjee C., Averin O., Kelleher N.L., and van der Donk W.A. Lacticin 481: in vitro reconstitution of lantibiotic synthetase activity. Science 303 (2004) 679-681
47. Yonezawa H., and Kuramitsu H.K. Genetic analysis of a unique bacteriocin, Smb, produced by Streptococcus mutans GS5. Antimicrob. Agents Chemother. 49 (2005) 541-548
48. Zimmermann N., and Jung G. The three-dimensional solution structure of the lantibiotic murein-biosynthesis-inhibitor actagardine determined by NMR. Eur. J. Biochem. 246 (1997) 809-819
49. Zimmermann N., Metzger J.W., and Jung G. The tetracyclic lantibiotic actagardine. 1H-NMR and 13C-NMR assignments and revised primary structure. Eur. J. Biochem. 228 (1995) 786-797